LONDON and WILMINGTON, N.C., March 16, 2015 /PRNewswire/ -- Chiltern, a leading global CRO, has become the only four-time five-category winner of the CRO Leadership award from Life Science Leader magazine. For the fourth straight year, Chiltern has been recognized by the drug development industry for excellence in Innovation, Quality, Reliability, Productivity and Regulatory.
"It has been an exciting year for Chiltern and we're proud to have earned this recognition from those who matter most – our customers," commented Chiltern CEO Dr. Jim Esinhart. "Our project teams have risen to the occasion once again as Chiltern has experienced significant growth and added specialization for 2015 toward delivering services that are Designed Around You. Chiltern is committed toward providing a flexible, customer-centric engagement because no two projects are the same."
The CRO Leadership Awards are presented annually based on an independent survey conducted by Nice Insight of over 2,300 industry executives. Award winners score in the top 10th percentile for select categories. Unlike other industry awards, which are given based on a subjective voting or nomination process, the only votes that count toward the CRO Leadership Awards are those of the pharmaceutical and biopharmaceutical companies using CRO services.
Chiltern, who works with biopharmaceutical developers of all sizes and geographies, was recognized for outstanding services particularly to the emerging and mid-size pharma and biotech sectors.
Dr. Esinhart concluded: "We work on a flexible platform where our employees are encouraged to be creative and service-oriented to meet client requirements. Even in a highly regulated industry, we're not locked into rigid processes. Chiltern creates an engagement that is truly unique to customer requirements. This is very appealing to sponsors advancing targeted therapeutics and seeking a focused, personalized, and professional engagement to achieve that goal."
About Chiltern:
Chiltern is a leading global CRO that listens to client needs in order to customize solutions for the Biopharma industry. With 33 years in service, Chiltern delivers from three specialized business units: Chiltern Biopharma, with deep therapeutic expertise for respiratory, anti-infectives / vaccines, ophthalmology, dermatology and other specialty areas; Chiltern Oncology, led by physicians, scientists and clinicians to uniquely manage all phases of hematologic and oncologic clinical drug development; and Chiltern Source, a world leader in tailored relationships for FSP, resourcing and staffing solutions. Chiltern's 2,200 engaged professionals work across 45 countries to deliver flexible, responsive solutions that are "Designed Around You".
Further information is available at: http://www.chiltern.com.
For more information contact:
Nicholas Spittal
Sr. Director, Global Commercial Affairs
Chiltern International Inc.
4000 Centregreen Way, Suite 300
Cary, NC 27513
USA
Tel: +1 (919) 462 8867
Email: [email protected]
SOURCE Chiltern
Share this article